Tafamidis
1. INDICATIONS AND USAGE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
SMILES: C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
Based on 30 units per month. US $743.93 vs India $39.19 per unit.
The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.
- Medicine savings over 6 months
- $126,854
- Estimated travel cost
- − $2,300
- Net savings after travel
- $124,554
Even after travel, you could come out ahead by about $124,554.
Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.
Tafamidis is filled about 109.4K times a year under Medicare Part D. At the prices above, that works out to roughly:
Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.